Results 241 to 250 of about 51,637 (256)
Some of the next articles are maybe not open access.

MYASTHENIA GRAVIS

The Neurologist, 2002
In myasthenia gravis (MG), the prototypic autoimmune disease, antibodies against acetylcholine receptors impair neuromuscular transmission and produce weakness. Although recognized for several hundred years, it has only been over the last three decades that effective treatments have become available for MG.This review summarizes the principles of ...
openaire   +2 more sources

MYASTHENIA GRAVIS

Optometry and Vision Science, 1974
W K, Engel   +5 more
openaire   +4 more sources

MYASTHENIA GRAVIS

The Lancet, 1966
A J, Strauss, P G, Kemp, S D, Douglas
openaire   +2 more sources

Myasthenia gravis

Current Opinion in Immunology, 1993
The cause of the myasthenics' pathogenic autoantibody response against the muscle acetylcholine receptor is an intriguing puzzle involving the thymus and its epithelial tumours, and possibly a variety of cross-reacting epitopes. Another fascinating challenge is to find ways of selectively inhibiting this response in the patients.
openaire   +2 more sources

Myasthenia gravis

Myasthenia gravis (MG) is a rare neuromuscular junction disorder that is characterized by fatigable weakness of muscles. People with MG experience various clinical manifestations based on the muscles involved. MG can be autoimmune, paraneoplastic, congenital, medication-related, or transient in the neonatal period due to the passive placental transfer ...
Mamatha, Pasnoor   +2 more
openaire   +2 more sources

Myasthenia gravis

DMW - Deutsche Medizinische Wochenschrift, 1955
M R, WESTERBERG, K R, MAGEE
openaire   +4 more sources

Myasthenia gravis

Annals of Emergency Medicine, 1982
J F, Nowakowski, A S, Yee
openaire   +2 more sources

Myasthenia Gravis

International Anesthesiology Clinics, 1968
openaire   +2 more sources

Myasthenia Gravis

Surgical Clinics of North America, 1980
A S, Wechsler, C W, Olanow
openaire   +2 more sources

Home - About - Disclaimer - Privacy